Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Jiatao Liao"'
Autor:
Chang Liu, Cuicui Liu, Jiatao Liao, Jiani C. Yin, Xianghua Wu, Xinmin Zhao, Si Sun, Huijie Wang, Zhihuang Hu, Yao Zhang, Hui Yu, Yang Shao, Jialei Wang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 171
Crizotinib remains one of the most commonly used targeted therapies for ALK fusion-positive patients. However, the mutational profiles and mechanisms of resistance to first-line crizotinib treatment remain to be thoroughly examined.We retrospectively